0.00

100.00% -53.01

Soleno Therapeutics Inc (SLNO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Soleno Therapeutics Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.

Previous Close:

$53.01

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$2.76B

Revenue:

$285.01M

Net Income/Loss:

$95.63M

P/E Ratio:

0.00

EPS:

1.762

Net Cash Flow:

$105.42M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

52-Week Range:

$0.00

$89.12

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name

Soleno Therapeutics Inc

Sector

Healthcare (1091)

Industry

Biotechnology (612)

Phone

650-213-8444

Address

100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA

Employee

182

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

SLNO's Discussions on Twitter

Compare SLNO vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLNO Soleno Therapeutics Inc	0.00	2.76B	285.01M	95.63M	105.42M	1.762
VRTX Vertex Pharmaceuticals Inc	480.25	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	663.09	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	876.25	54.58B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	183.95	39.73B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	288.06	39.89B	4.29B	577.22M	641.34M	4.2086

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-25	Initiated	Wolfe Research	Outperform
Oct-07-25	Initiated	Goldman	Buy
Aug-20-25	Initiated	Wells Fargo	Overweight
Jun-23-25	Initiated	TD Cowen	Buy
Mar-05-25	Resumed	Stifel	Buy
Dec-02-24	Reiterated	Robert W. Baird	Outperform
Dec-02-24	Reiterated	Stifel	Buy
Sep-03-24	Initiated	H.C. Wainwright	Buy
May-10-24	Initiated	Robert W. Baird	Outperform
Feb-05-24	Initiated	Piper Sandler	Overweight
Jan-23-24	Initiated	Stifel	Buy
Nov-21-23	Resumed	Guggenheim	Buy
Sep-29-20	Initiated	Guggenheim	Buy
Jan-10-20	Initiated	Craig Hallum	Buy
Dec-23-19	Initiated	Oppenheimer	Outperform
Feb-13-18	Reiterated	Maxim Group	Buy

View All

Soleno Therapeutics Inc Stock (SLNO) Latest News

Jul 11, 2026

Price to earnings forward of Soleno Therapeutics Inc – LS:A3DS0P - TradingView

Jul 11, 2026

Jul 10, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jul 10, 2026

Jul 09, 2026

Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LL - The National Law Review

Jul 09, 2026

Trading Systems Reacting to (SLNO) Volatility - Stock Traders Daily

Jul 09, 2026

2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation | Press Release - Stockhouse

Jul 09, 2026

Jul 08, 2026

Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo

Jul 08, 2026

Jul 07, 2026